Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D03NLV
|
|||
| Former ID |
DIB009437
|
|||
| Drug Name |
KDT-501
|
|||
| Synonyms |
Protein kinase inhibitor (inflammatory disorders), KinDex Therapeutics; Protein kinase inhibitor (metabolic disorders),KinDex Therapeutics
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Inflammation [ICD-11: 1A00-CA43.1] | Phase 2 | [1] | |
| Type-2 diabetes [ICD-11: 5A11; ICD-9: 250] | Phase 2 | [2] | ||
| Company |
KinDEx Therapeutics
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C21H33KO5
|
|||
| Canonical SMILES |
CC(C)CCC1C(=O)C(=C(C1(C(=O)CCC(C)C)[O-])O)C(=O)CC(C)C.[K+]
|
|||
| InChI |
1S/C21H33O5.K/c1-12(2)7-9-15-19(24)18(16(22)11-14(5)6)20(25)21(15,26)17(23)10-8-13(3)4;/h12-15,25H,7-11H2,1-6H3;/q-1;+1/t15-,21+;/m1./s1
|
|||
| InChIKey |
OBRIOHODJVKWGS-WSZABJOTSA-N
|
|||
| CAS Number |
CAS 1374228-86-0
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT02444910) Effects of KDT501 on Metabolic Features in Insulin Resistant Subjects. U.S. National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.